ACI-7104.056
ACI-7104 Protein Target: alpha-synuclein
AC Immune
Most recent annual filing: 2026-03-13
- ACI-7104.056 VacSYn topline2H 2026ACI-7104.056 VacSYn topline, 2H 2026, thesis-defining
- Morphomer a-syn aggregation inhibitor guidance2H 2026Morphomer a-syn aggregation inhibitor guidance, 2H 2026, routine
- ACI-15916 PET Ph1 readoutLate 2026ACI-15916 PET Ph1 readout, Late 2026, material
- ACI-19764 Ph1 readout1H 2027ACI-19764 Ph1 readout, 1H 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (10 active programs)
ACI-24.060
ACI-24 Protein Target: amyloid beta
semorinemab
ACI-35.030 · JNJ-64042056 · JNJ-2056 Protein Target: phosphorylated Tau, Tau
ACI-19764
Small Molecule Target: NLRP3
- Undisclosed indication
crenezumab
Protein Target: amyloid beta
PI-2620
LNTH-2620 Small Molecule Target: Tau
ACI-12589
Small Molecule Target: alpha-synuclein
ACI-15916
Small Molecule Target: alpha-synuclein
ACI-19626
Small Molecule Target: TDP-43
Technology platforms
SupraAntigen
Liposome-based antigen presentation platform generating conformation-specific antibodies for active immunotherapy targeting misfolded proteins in neurodegenerative diseases; focus areas include Alzheimer's disease and Parkinson's disease
Targets: amyloid beta, phosphorylated Tau, alpha-synuclein
Morphomer
Small molecule discovery platform selecting brain-penetrant compounds targeting misfolded protein aggregates intracellularly; generates both therapeutic and diagnostic (PET tracer) candidates for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, FTD, and ALS
Targets: Tau, alpha-synuclein, TDP-43, NLRP3
Morphomer · Lilly
Small-molecule platform targeting intracellular protein misfolding aggregates; current focus on Tau and alpha-synuclein aggregation inhibitors for neurodegenerative disease
Targets: Tau, alpha-synuclein
Biotech Distilled coverage (5)
- 2026-08-20 UPDATE: AC Immune (ACIU) — The Sleeper Wakes Up at ≤10mg 🔒 Paid
- 2026-08-12 UPDATE: AC Immune (ACIU) — The FDA Opens the Door for the PD Vaccine 🔒 Paid
- 2026-08-06 UPDATE: AC Immune (ACIU) - Two Shots, Five Months, CHF 75.4M 🔒 Paid
- 2026-06-30 UPDATE: AC Immune (ACIU) - The ABATE Tell 🔒 Paid
- 2026-06-01 AC Immune SA (ACIU) — Scientific Deep Dive for ACI-7104.056 and the SupraAntigen/Morphomer Pipeline 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.